WALTHAM, Mass. --(BUSINESS WIRE)-- NeuroMetrix, Inc. (Nasdaq: NURO) reported today the Quell™ app is now available in the Apple app store. Quell is an over-the-counter wearable pain relief device that utilizes proprietary non-invasive neurostimulation technology to provide relief from chronic pain.
Shares of Common Stock and Listed Warrants Have Begun Trading on a Split-Adjusted Basis on The NASDAQ Capital Market BOSTON --(BUSINESS WIRE)-- NeuroMetrix, Inc. (NASDAQ:NURO) today confirmed that it has consummated a one-for-four reverse split of its common stock.
NeuroMetrix Completes 510(k) Clearance Process for SENSUS™ Pain Management System WALTHAM, Mass. --(BUSINESS WIRE)--Nov. 29, 2012-- NeuroMetrix, Inc. (Nasdaq: NURO), www.neurometrix.com , a medical device company focused on the diagnosis and treatment of the neurological complications of diabetes,
WALTHAM, Mass. --(BUSINESS WIRE)-- NeuroMetrix , Inc. (NASDAQ:NURO) today provided commentary on its Quell ® partnership strategy. The Company has five objectives for its Quell partnership strategy. Support NeuroMetrix efforts to build the Quell brand in the North America market Make Quell
WALTHAM, Mass. --(BUSINESS WIRE)-- NeuroMetrix, Inc. ( NASDAQ : NURO, NUROW) announced that it has closed its previously announced private placement to a healthcare dedicated institutional investor of 7,000 shares of Series E convertible preferred stock at a price of $1,000 per share, and warrants
WALTHAM, Mass. --(BUSINESS WIRE)-- NeuroMetrix , Inc. (NASDAQ: NURO) today closed a $3.5 million private placement of 3,500 shares of Series F convertible preferred stock at a price of $1,000 per share that are convertible into 1,330,798 shares of common stock at a conversion price of $2.63 per
WALTHAM, Mass. --(BUSINESS WIRE)-- NeuroMetrix , Inc. (Nasdaq: NURO) reported that it has closed its previously announced private placement of preferred stock and warrants. The Company sold to a healthcare dedicated institutional investor 21,300 shares of Series D convertible preferred stock at a
WALTHAM, Mass. --(BUSINESS WIRE)-- NeuroMetrix , Inc. (Nasdaq:NURO) today reported that it has closed its previously announced underwritten public offering. The Company sold 147,000 units, with each unit consisting of one share of Series B convertible preferred stock and 99 warrants exercisable for
WALTHAM, Mass. --(BUSINESS WIRE)-- NeuroMetrix , Inc. (Nasdaq: NURO) reported that it has closed its previously announced private placement of preferred stock and warrants. The Company sold to a healthcare dedicated institutional investor 13,800 shares of Series C convertible preferred stock at a
